Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04936308
Registration number
NCT04936308
Ethics application status
Date submitted
16/06/2021
Date registered
23/06/2021
Titles & IDs
Public title
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Query!
Scientific title
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent
Query!
Secondary ID [1]
0
0
2021-000482-32
Query!
Secondary ID [2]
0
0
CR109039
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SOLSTICE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Psoriatic
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - Placebo
Experimental: Group 1: Guselkumab and Placebo - Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
Experimental: Group 2: Guselkumab - Participants will receive guselkumab SC.
Experimental: Group 3: Placebo Followed by Guselkumab - Participants will receive placebo SC and will cross over to receive guselkumab SC.
Treatment: Drugs: Guselkumab
Participants will receive guselkumab as SC injection.
Treatment: Drugs: Placebo
Participants will receive matching placebo as SC injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 20 Response at Week 24
Query!
Assessment method [1]
0
0
The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent (%) improvement from baseline in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and CRP.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Participants who Achieve a Psoriasis Response of IGA Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 at Baseline
Query!
Assessment method [1]
0
0
Psoriasis response is defined as an Investigator's Global Assessment (IGA) psoriasis score of 0 (cleared) or 1 (minimal) and \>=2- grade reduction from baseline. The IGA documents the investigator's assessment of the participants psoriasis and lesions are graded for induration, erythema and scaling, each using a 5-point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Percentage of Participants who Achieve PASI 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Query!
Assessment method [2]
0
0
Psoriasis Area and Severity Index (PASI) is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area is assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in HAQ-DI Score at Week 24
Query!
Assessment method [3]
0
0
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Query!
Timepoint [3]
0
0
Baseline and Week 24
Query!
Secondary outcome [4]
0
0
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Query!
Assessment method [4]
0
0
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a PCS with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Query!
Timepoint [4]
0
0
Baseline and Week 24
Query!
Secondary outcome [5]
0
0
Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score at Week 24
Query!
Assessment method [5]
0
0
The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Query!
Timepoint [5]
0
0
Baseline and Week 24
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
Query!
Assessment method [6]
0
0
MDA is considered achieved if at least 5 of the following 7 criteria were met at the analysis visit: tender joint count \<=1; swollen joint count \<=1; psoriasis activity and severity index \<=1; patient's pain VAS score of \<=15; patient's global disease activity VAS (arthritis and psoriasis) score of \<=20; HAQ-DI \<=0.5; and tender entheseal points \<=1.
Query!
Timepoint [6]
0
0
Week 24
Query!
Secondary outcome [7]
0
0
Percentage of Participants who Achieve ACR 20 Response at Week 16
Query!
Assessment method [7]
0
0
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform task in that area), and CRP.
Query!
Timepoint [7]
0
0
Week 16
Query!
Secondary outcome [8]
0
0
Percentage of Participants who Achieve ACR 50 Response at Week 16
Query!
Assessment method [8]
0
0
ACR 50 response is defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Query!
Timepoint [8]
0
0
Week 16
Query!
Secondary outcome [9]
0
0
Percentage of Participants who Achieve ACR 50 Response at Week 24
Query!
Assessment method [9]
0
0
ACR 50 response is defined as \>=50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Query!
Timepoint [9]
0
0
Week 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants who Achieve ACR 70 Response at Week 24
Query!
Assessment method [10]
0
0
ACR 70 response is defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Query!
Timepoint [10]
0
0
Week 24
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Reasonably Related AEs, as a Measure of Safety and Tolerability
Query!
Assessment method [11]
0
0
Percentage of participants with AEs, SAEs reasonably related AEs will be assessed. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product. Reasonably related AEs are those AEs which are judged related to study treatment by the investigator.
Query!
Timepoint [11]
0
0
Up to 112 weeks
Query!
Secondary outcome [12]
0
0
Percentage of Participants With AEs leading to Discontinuation of Study Intervention
Query!
Assessment method [12]
0
0
Percentage of participants with AEs leading to discontinuation of study intervention will be reported.
Query!
Timepoint [12]
0
0
Up to 112 weeks
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Infections
Query!
Assessment method [13]
0
0
Percentage of participants with infections will be reported.
Query!
Timepoint [13]
0
0
Up to 112 weeks
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Injection-site Reactions
Query!
Assessment method [14]
0
0
Percentage of participants with injection-site reactions will be reported. An injection-site reaction is any adverse reaction at a subcutaneous (SC) study intervention injection-site.
Query!
Timepoint [14]
0
0
Up to 100 weeks
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Change from Baseline in Clinical Laboratory Abnormalities
Query!
Assessment method [15]
0
0
Percentage of participants with change from baseline in clinical laboratory abnormalities including chemistry and hematology will be reported.
Query!
Timepoint [15]
0
0
Up to 112 weeks
Query!
Secondary outcome [16]
0
0
Percentage of participants With Laboratory Abnormalities With Maximum Toxicity Grades as per Common Terminology Criteria for Adverse Events (CTCAE) Toxicity
Query!
Assessment method [16]
0
0
Percentage of participants with laboratory abnormalities (hematology, chemistry) with maximum toxicity grades as per CTCAE will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.
Query!
Timepoint [16]
0
0
Up to 112 weeks
Query!
Secondary outcome [17]
0
0
Serum Guselkumab Concentration
Query!
Assessment method [17]
0
0
Serum guselkumab concentration will be measured.
Query!
Timepoint [17]
0
0
Up to 112 weeks
Query!
Secondary outcome [18]
0
0
Percentage of Participants With Anti-guselkumab Antibodies
Query!
Assessment method [18]
0
0
Percentage of participants with anti-guselkumab antibodies to guselkumab will be reported.
Query!
Timepoint [18]
0
0
Up to 112 weeks
Query!
Eligibility
Key inclusion criteria
* Have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
* Have active PsA as defined by: at least 3 swollen joints and at least 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory
* Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
* Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeters (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis
* Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as presence of active PsA despite previous treatment with one prior anti-TNF alpha agent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy in the treatment of PsA, including but not limited to rheumatoid arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic lupus erythematosus, or Lyme disease
* Has received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (or biosimilars)
* Has ever received Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor
* Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
* Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
* Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (example, mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
16/07/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
453
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Southern Clinical Research - Hobart
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [3]
0
0
Skin Health Institute Inc. - Melbourne
Query!
Recruitment hospital [4]
0
0
Eastern Health - Box Hill Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
3053 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3128 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Mexico
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oklahoma
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
West Virginia
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Ciudad de Mendoza
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
San Miguel De Tucuman
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Pleven
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Plovdiv
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Ruse
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Sofia
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Breclav
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Hlucin
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Ostrava
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Pardubice
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Praha 2
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Uherske Hradiste
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Zlin
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Budapest
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Debrecen
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Gyula
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Kistarcsa
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szeged
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Szekesfehervar
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Veszprem
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Haifa
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Hifa
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Kfar-Sava
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Ramat Gan
Query!
Country [50]
0
0
Malaysia
Query!
State/province [50]
0
0
Batu Caves
Query!
Country [51]
0
0
Malaysia
Query!
State/province [51]
0
0
George Town
Query!
Country [52]
0
0
Malaysia
Query!
State/province [52]
0
0
Ipoh
Query!
Country [53]
0
0
Malaysia
Query!
State/province [53]
0
0
Seremban
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Bytom
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Elblag
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Krakow
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Lodz
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Nadarzyn
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Nowa Sol
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Poznan
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Swidnik
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Warsaw
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Warszawa
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Wroclaw
Query!
Country [65]
0
0
Puerto Rico
Query!
State/province [65]
0
0
San Juan
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Barnaul
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Chelyabinsk
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Kemerovo
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Korolev
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Krasnodar
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Krasnoyarsk
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Moscow
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Orenburg
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Rostov
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Saratov
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Smolensk
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
St. Petersburg
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Tolyatti
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Tula
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Ufa
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Barakaldo
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Madrid
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Málaga
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Santiago de Compostela
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Sevilla
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Valencia
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Adana
Query!
Country [88]
0
0
Turkey
Query!
State/province [88]
0
0
Ankara
Query!
Country [89]
0
0
Turkey
Query!
State/province [89]
0
0
Antalya
Query!
Country [90]
0
0
Turkey
Query!
State/province [90]
0
0
Bursa
Query!
Country [91]
0
0
Turkey
Query!
State/province [91]
0
0
Denizli
Query!
Country [92]
0
0
Turkey
Query!
State/province [92]
0
0
Eskisehir
Query!
Country [93]
0
0
Turkey
Query!
State/province [93]
0
0
Istanbul
Query!
Country [94]
0
0
Turkey
Query!
State/province [94]
0
0
Kocaeli
Query!
Country [95]
0
0
Turkey
Query!
State/province [95]
0
0
Konya
Query!
Country [96]
0
0
Ukraine
Query!
State/province [96]
0
0
Cherkasy
Query!
Country [97]
0
0
Ukraine
Query!
State/province [97]
0
0
Kharkiv
Query!
Country [98]
0
0
Ukraine
Query!
State/province [98]
0
0
Khmelnytsky
Query!
Country [99]
0
0
Ukraine
Query!
State/province [99]
0
0
Kryvyi Rih
Query!
Country [100]
0
0
Ukraine
Query!
State/province [100]
0
0
Kyiv
Query!
Country [101]
0
0
Ukraine
Query!
State/province [101]
0
0
Lutsk
Query!
Country [102]
0
0
Ukraine
Query!
State/province [102]
0
0
Odessa
Query!
Country [103]
0
0
Ukraine
Query!
State/province [103]
0
0
Poltava
Query!
Country [104]
0
0
Ukraine
Query!
State/province [104]
0
0
Vinnytsya
Query!
Country [105]
0
0
Ukraine
Query!
State/province [105]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04936308
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04936308